Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are hepatic manifestations of metabolic syndrome and are increasing globally.1,2 Patients with NAFLD/NASH often present with either type 2 diabetes (T2D) or have insulin resistance and elevated fasting insulin levels, which are all established precursors for the development of diabetes and for adverse macrovascular sequalae.3 –5 NASH, T2D, and insulin resistance are thought to be growing in incidence and severity because of the increased availability of nutrients and consequent overnutrition.

Source: Journal of Hepatology - November 5, 2019 Category: Gastroenterology Authors: Stephen A. Harrison, Naim Alkhouri, Beth A. Davison, Arun Sanyal, Christopher Edwards, Jerry R. Colca, Bo Hyun Lee, Rohit Loomba, Kenneth Cusi, Orville Kolterman, Gad Cotter, Howard C. Dittrich Source Type: research